ArticleAnnals of hematology2025
Secondary neoplasms in mycosis fungoides: evaluating risk factors and phototherapy impact in a comparative study.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with mycosis fungoides (MF) are at an increased risk of developing secondary neoplasms. We conducted a comparative analysis between MF patients with and without secondary neoplasms and non-MF patients to assess secondary neoplasm occurrence and identify potential risk factors. We aimed to evaluate the prevalence of secondary neoplasms and investigate associated risk factors in MF patients. Demographic data, treatments, phototherapy details, neoplasm occurrence and detection time, and mortality rates were collected and retrospectively analyzed for 252 MF and 278 control patients. The prevalence of secondary neoplasms was significantly higher in the MF group (13.9%) compared to the control group (3.6%) (p < 0.001). MF patients with neoplasms had a higher average age and older age at MF diagnosis (p = 0.003 and 0.016, respectively). Phototherapy type showed no significant association with neoplasm presence. Elevated initial and final beta-2 microglobulin levels were observed in MF patients with neoplasms (p = 0.002 and 0.005, respectively). MF patients have a higher risk of developing secondary neoplasms compared to controls. Risk increases with older age at MF diagnosis and elevated beta-2 microglobulin levels. Phototherapy was not associated with the development of secondary neoplasms in MF patients. MF patients with secondary neoplasms exhibit higher mortality rates, underscoring the importance of early detection and vigilant monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.